NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
22 May 2017

AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase (recAP) Phase II trial in Acute Kidney Injury

AM‐Pharma B.V., announced completion of recruitment in the adaptive Phase II trial to treat sepsis patients with Acute Kidney Injury (AKI).
04 May 2017

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

Vivet Therapeutics (‘Vivet’), announced it has raised €37.5 million in a Series A financing round.
01 May 2017

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals, Inc. today announced positive top-line results from its confirmatory Phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery.
21 Apr 2017

STAT-Dx Unveils New In-Vitro Diagnostic System DiagCORE®

TAT-Dx, is unveiling DiagCORE®, its fully-integrated platform for multiplex real-time PCR diagnosis, at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
06 Apr 2017

TiGenix reports 2016 full year results

TiGenix NV today reported its business and financial highlights for 2016 and post year-end events.
05 Apr 2017

Aelix Therapeutics appoints Dr. Ian McGowan as Chief Medical Officer

Aelix Therapeutics, today announces the appointment of Dr. Ian McGowan as Chief Medical Officer, effective March 1, 2017.
Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma<
30 Mar 2017

Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma

Aura Biosciences, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light-activated AU-011.
23 Mar 2017

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

BioClin Therapeutics, Inc., announced today the closing of a $30 million Series B financing.

22 Mar 2017

Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102

Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that it has successfully completed its phase 1 trial with MIN-102.
20 Mar 2017

MedLumics Secures 34.4 Million Euros in Series B Funding

MedLumics announced today that it has raised 34.4 million Euros in financing that will be used to help advance the product and clinical development of the company’s AblaView catheter

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка